Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 91,399

Document Document Title
WO/2018/185270A1
The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors ...  
WO/2018/187802A1
The present invention relates to noninvasive microbiome analyses of Barrett's esophagus (BE) patients in which changes in the relative abundance of certain bacteria indicate a disease likelihood or pathogenic state. Additional aspects of...  
WO/2018/185098A1
The present invention relates to a pharmaceutical combination comprising: (a) a PPAR agonist; (b) a p38 kinase inhibitor; and optionally (c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of ...  
WO/2018/185135A1
The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.  
WO/2018/186322A1
The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bi...  
WO/2018/187228A1
Biomarkers to screen for, identify, and/or characterize lung cancer in a subject are disclosed. Also disclosed herein are methods for distinguishing lung cancer from another disease. Also disclosed herein are methods for detecting metast...  
WO/2018/187388A1
The present invention relates to the use of redox agents for purification of the CRM 197 variant of diphtheria toxin. The invention further relates to multi-step purification of CRM 197 from bacterial fermentates.  
WO/2018/184074A1
The invention relates to a method for treating a side effect of chimeric antigen receptor (CAR) T cell therapy, the method comprising administering a mesenchymal stem cell (MSC) to a subject who has been or is being administered CAR T ce...  
WO/2018/187728A1
his invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment o...  
WO/2018/185030A1
The present invention relates to the treatment of type 2 inflammation. Based on the role of ILC2 in the induction of airway inflammation, the inventors investigate whether ILC2 could be influenced by sex hormones. In this study (effected...  
WO/2018/185516A1
The invention relates to methods for treating cardiovascular toxicity induced by anti-cancer and anti-angiogenic compound. The inventors explored the cardiotoxicity induced by the antiangiogenic therapy, sunitinib, in the mouse heart. Th...  
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/187158A1
The present application relates to an anti-endoglin antibody in combination with an anti-PD-1 antibody. The present application relates to an anti-endoglin antibody in combination with an anti-PD-L1 antibody. The present application rela...  
WO/2018/185701A1
Invented is a method of treating cough; including acute cough, sub-acute cough and chronic cough, in a mammal in need thereof which comprises the administration of a therapeutically effective amount of a selected TRPV4 antagonist to such...  
WO/2018/184678A1
The invention relates to methods, composition and uses for the of treatment of cancer selected from the group consisting of HCC, RCC, NSCLC, ovarian cancer, CCA, PTC and FTC in a subject, which comprise administering an HDAC inhibitor in...  
WO/2018/186032A1
The present invention provides an anticancer agent based on a novel mechanism. Specifically, the present invention relates to an inhibitor that inhibits gene expression regulation by SWI/SNF complex-dependent NF-κB or corepressor comple...  
WO/2018/182776A1
Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to...  
WO/2018/183908A1
Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in...  
WO/2018/178925A1
The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-( 4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropy l-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one ...  
WO/2018/183194A1
Methods of implanting therapeutic cells in a subject and methods of preparing pancreatic islet cells for implantation into a subject, prior to implantation into a subject, are provided herein.  
WO/2018/181380A1
To provide an edible composition for intestinal bacteria which ameliorates intestinal flora (intestinal bacterial flora) and promotes the diversity thereof so as to contribute to human health. A composition comprising: a natural dietary ...  
WO/2018/183065A1
The present disclosure is directed to methods of treating malignant melanoma by irradiating sites to which melanoma cells have become locally advanced, surgically undesirable, or have metastasized. In various embodiments of the invention...  
WO/2018/178676A1
It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dos...  
WO/2018/183947A1
Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of...  
WO/2018/183891A1
In one aspect, the present invention provides a method for preventing or treating cancer in a subject. In some embodiments, the method comprises administering a therapeutically effective amount of the Chk1 inhibitor Compound 1. In other ...  
WO/2018/183367A1
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), their pharmaceutical compositions, and methods of treating cystic fibrosis in patients with residual function mutations.  
WO/2018/183701A1
The present disclosure provides compounds represented by Formula (I): (Formula(I) and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. Th...  
WO/2018/178668A1
The invention is based on the finding that co-administration of 6-β-naltrexol alongside vitamin D together with a chemotherapeutic agent, results in a further reduction in lung cancer cell growth. The combination of 6-β-naltrexol with ...  
WO/2018/181542A1
[Problem]To provide a combination of drugs with a higher antitumor effect. [Solution]This adjuvant composition comprises a pH-sensitive carrier and a substance for activating a natural immunity, wherein the pH-sensitive carrier is used t...  
WO/2018/178690A1
The present invention provides an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent wherein the agent is selected from the list consisting of 6-β-naltrexol, nalox...  
WO/2018/178233A1
The invention relates to the use of low doses of (+)-α-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome. The invention provides (+)-α-Dihydrotetrabenazine or pharmaceutically acceptable salt the...  
WO/2018/183927A1
Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More...  
WO/2018/181420A1
Provided is a liposome useful as a vaccine adjuvant. More specifically, provided is a liposome which comprises a lipid bilayer containing dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugate compound in which a low...  
WO/2018/183901A1
A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the poten...  
WO/2018/183041A1
The present invention relates to treatment of Trop-2 postive cancers with the combination of anti-Trop-2 ADC and a Rad51 inhibitor. Preferably the drug conjugated to the antibody is SN-38, and the ADC is sacituzumab govitecan. The ADC ma...  
WO/2018/178194A1
The invention is in the field of neuroregenerative medicine. Controlling the fate of neural stem cells represents a key therapeutic strategy in neuroregenerative medicine. The inventors used in silico genomic approaches, searchable platf...  
WO/2018/178250A1
The invention describes anti-cancer therapies comprising using a SMAC mimetic in combination with a PD-1 antagonist, each as described herein.  
WO/2018/172559A2
There is disclosed buthionine sulfoximine (BSO) for use in a method of treatment of cancer, HIV or a rheumatic disease. The method comprises administering (a) BSO at a dosage of less than or equal to 50mg/kg, and (b) a metallodrug at a c...  
WO/2018/176065A1
mRNA polymer complexes and drug delivery systems are disclosed herein that include a cationic polymer electrostatically complexed to an mRNA molecule that encodes a desired protein. Also disclosed herein are methods of treating as well a...  
WO/2018/173985A1
The present invention relates to a beetroot-containing food composition, and the beetroot-containing food composition comprises beetroot and salt and/or an additional nitrate-containing food material with or without a vitamin supplement....  
WO/2018/175833A1
This invention relates to inhibition of the complement signaling using anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contac...  
WO/2018/175969A1
The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h exahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin- 8-yl)-butan-1-one ...  
WO/2018/173052A1
Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and meth...  
WO/2018/175932A1
The present invention provides compositions, systems, kits, and methods for expression of one or more biomolecules in a subject, human or non-human mammal, (e.g., at therapeutic levels for the extended periods of time required to produce...  
WO/2018/175271A1
The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be us...  
WO/2018/175403A1
The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins. In some embodiments, the IL-3...  
WO/2018/174408A1
The present invention relates to an antibody that specifically binds to death receptor 5 (DR5) and has a function of killing cancer cells. Specifically, provided are an anti-DR5 antibody or antigen-binding fragment thereof, and a use of ...  
WO/2018/171555A1
Provided are methods and compositions, e.g., kits, for determining the abundance of certain bacterial species in a cancer patient's gut and methods of using such information to predict the cancer patient's response to immunotherapy. Prov...  
WO/2018/174219A1
The present invention provides a drug/a method for treating cancer arrived at by combining a compound represented by general formula (1), which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor. The present invention pro...  
WO/2018/172508A1
The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 correlates with melanoma progression and with a poorer survival rate in metastatic mel...  

Matches 1 - 50 out of 91,399